Immunic, Inc. (IMUX)
Immunic appoints biopharmaceutical executive Jon Congleton to board
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to its board of directors, as the company advances its multiple sclerosis program through late-stage development. Congleton brings nearly four decades of experience in the biopharmaceutical industry, with a background spanning drug development, commercialization, and executive leadership, according to Immunic.
Immunic secures European patent for MS drug candidate vidofludimus calcium
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Tuesday the European Patent Office has granted a key patent covering dosing regimens for its experimental multiple sclerosis treatment vidofludimus calcium, extending potential market protection for the drug candidate in Europe to 2038. The patent, EP3713554, protects label-relevant dosing regimens of vidofludimus calcium and broadly covers the compound and its salt, solvate and free acid forms when used according to the approved label, the company said.
Immunic to present at healthcare investor conferences in March
Immunic Inc (NASDAQ:IMUX), a late-stage biotechnology company developing oral treatments for neurological and gastrointestinal diseases, will participate in two investor conferences this month. Chief executive Daniel Vitt and president Jason Tardio will take part in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami on 11 March, with one-on-one investor meetings also scheduled across the event, which runs from 8 to 11 March.
Immunic secures $400M to support late-stage MS trials - ICYMI
Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support completion of late-stage trials and prepare the company for a potential commercial launch of vidofludimus calcium in multiple sclerosis. Speaking to Proactive, CEO Dr Daniel Vitt described the financing as “a transformative transaction for the company,” noting that $200 million has already been received, with the remainder available in a second tranche.
Immunic sets stage for phase 3 MS data readout after $400M financing
Immunic Inc (NASDAQ:IMUX) said it is entering a pivotal period for its multiple sclerosis program after securing up to $400 million in new financing and advancing its lead drug into late-stage development, with key data expected by the end of 2026. The biotechnology company's oral candidate, vidofludimus calcium (IMU-838), is currently being evaluated in the twin phase 3 ENSURE-1 and ENSURE-2 trials in relapsing multiple sclerosis (RMS).
Immunic closes $200M private placement to fund late-stage MS trials
Immunic Inc (NASDAQ:IMUX) said on Tuesday it has closed a previously disclosed private placement financing, raising $200 million upfront with the potential to secure up to an additional $200 million. The New York-based biotechnology company issued just over 229 million pre-funded warrants at a price of $0.873 each, generating gross upfront proceeds of $200 million.
Immunic MS trial shows reduced brain lesions - ICYMI
Immunic Inc (NASDAQ:IMUX)'s chief medical officer Dr Andreas Muehler talked with Proactive about new data presented at the ACTRIMS Forum in San Diego, highlighting findings from the company's phase 2 CALIPER trial in progressive multiple sclerosis (MS). Proactive: Hello, you're watching Proactive.
Immunic to raise up to $400M to fund late-stage MS trials, commercial push
Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds as the biotechnology company works to transition toward commercialization of its multiple sclerosis pipeline. The financing includes $200 million in upfront proceeds through the issuance of 229,076,000 pre-funded warrants priced at $0.873 each, with the potential for an additional $200 million from accompanying warrants if exercised.
Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS
Immunic Inc (NASDAQ:IMUX) said it will present additional analyses from its Phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis (PMS) at the ACTRIMS Forum 2026, which is being held from February 5 to 7 in San Diego. Vidofludimus calcium is described by Immunic as a nuclear receptor-related 1 (Nurr1) activator and selective dihydroorotate dehydrogenase (DHODH) inhibitor.
Immunic targets MS market with Phase 3 data - ICYMI
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's major milestones in 2025 and key expectations for 2026. He highlighted the significance of the phase 2 CALLIPER study, which demonstrated a 31% reduction in confirmed disability worsening in patients with progressive multiple sclerosis (MS), and a 34% reduction in those without baseline gadolinium lesions.
Immunic looks to 2026 data as late-stage MS program advances
Immunic Inc (NASDAQ:IMUX) said on Wednesday it is entering a pivotal phase for its lead multiple sclerosis drug as the biotech company prepares for key clinical readouts that could shape its longer-term growth strategy. The Nasdaq-listed company said it has completed patient enrollment in two late-stage Phase 3 trials of vidofludimus calcium, an oral therapy being tested in relapsing multiple sclerosis (RMS), and expects synchronized top-line results by the end of 2026.
Immunic's long-term treatment hope for multiple sclerosis – ICYMI
Immunic Inc (NASDAQ:IMUX) earlier this week highlighted the long-term clinical potential of its lead compound vidofludimus calcium in treating multiple sclerosis (MS). Speaking to Proactive, Chief Scientific Officer Dr.
